Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2% – What’s Next?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) dropped 8.2% on Tuesday . The stock traded as low as $44.50 and last traded at $44.2410. Approximately 385,880 shares were traded during trading, a decline of 80% from the average daily volume of 1,910,791 shares. The stock had previously closed at $48.18.

Crinetics Pharmaceuticals News Summary

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Company reported strong PALSONIFY launch execution with unaudited preliminary Q4 net product revenue of >$5M and >200 enrollment forms; management also disclosed positive Phase 2 topline data for atumelnant (large androstenedione reductions and successful glucocorticoid dose reductions with no hepatic transaminase events reported). GlobeNewswire: Strong PALSONIFY Launch & Atumelnant Results
• Positive Sentiment: An influential sell‑side firm, Morgan Stanley, raised its price target to $80 and set an “overweight” rating, implying substantial upside versus the recent share price — this boosts investor sentiment on CRNX’s commercial and clinical trajectory. Benzinga: Morgan Stanley Raises PT
• Neutral Sentiment: Management hosted an investor call / provided a business update and posted a transcript/slideshow outlining PALSONIFY launch progress and Phase 2 atumelnant results — useful for modeling uptake and future revenue but not immediate cash impact. Seeking Alpha: PALSONIFY Launch & Atumelnant Transcript
• Negative Sentiment: Crinetics filed a proposed underwritten public offering to sell $350M of common stock (with a 30‑day option for an additional $52.5M). Because all shares are to be sold by the company, the deal raises near‑term dilution and downward pressure on the share price until completion or use of proceeds is clarified. GlobeNewswire: Proposed $350M Offering
• Negative Sentiment: Market reports noted a near‑term sell reaction after the offering announcement; that immediate supply overhang is the most likely driver of today’s downward move despite the upbeat commercial/clinical news. Investing.com: Stock Ticks Lower After Offering

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Oppenheimer upped their price objective on shares of Crinetics Pharmaceuticals from $73.00 to $87.00 and gave the stock an “outperform” rating in a report on Tuesday, September 30th. Morgan Stanley lifted their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday. Citizens Jmp dropped their price target on Crinetics Pharmaceuticals from $143.00 to $108.00 and set a “market outperform” rating on the stock in a research report on Friday, November 7th. Finally, JMP Securities upped their price target on Crinetics Pharmaceuticals from $86.00 to $143.00 and gave the stock a “market outperform” rating in a research note on Friday, September 26th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $77.82.

Crinetics Pharmaceuticals Stock Performance

The business’s fifty day moving average price is $45.47 and its 200-day moving average price is $38.04. The stock has a market cap of $4.32 billion, a PE ratio of -10.04 and a beta of 0.20.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.11). The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.39 million. During the same quarter last year, the business posted ($0.96) EPS. Analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Crinetics Pharmaceuticals news, insider Dana Pizzuti sold 5,000 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $42.66, for a total value of $213,300.00. Following the transaction, the insider owned 66,270 shares of the company’s stock, valued at approximately $2,827,078.20. This represents a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC lifted its stake in shares of Crinetics Pharmaceuticals by 523.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 842 shares of the company’s stock worth $35,000 after purchasing an additional 707 shares during the period. Headlands Technologies LLC purchased a new stake in Crinetics Pharmaceuticals during the second quarter valued at approximately $30,000. Covestor Ltd raised its position in Crinetics Pharmaceuticals by 23,983.3% in the third quarter. Covestor Ltd now owns 1,445 shares of the company’s stock worth $60,000 after acquiring an additional 1,439 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Crinetics Pharmaceuticals during the 2nd quarter worth $45,000. Finally, Abich Financial Wealth Management LLC purchased a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $68,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.